NICE gives go-ahead for Lucentis

The National Institute for Health and Clinical Excellence has said primary care trusts should fund the use of ranibizumab - commonly known as Lucentis - for the treatment of wet age-related macular degeneration if certain conditions apply.

You need to be an HSJ subscriber to read more

HSJ

Subscribe to read the full article

With an HSJ subscription you’ll get access to:

  • Expert Briefing newsletters, covering nine topics and regions
  • Weekly Catch Up – a summary of the week’s most important stories
  • Unlimited access to hsj.co.uk
  • The HSJ app

Enquire about multi-user access